nach oben

Erschienen in:

04.07.2018 | Original Article

Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancer

verfasst von: Lourdes Barrera, Edgar Montes-Servín, Juan-Manuel Hernandez-Martinez, Mario Orozco-Morales, Elizabeth Montes-Servín, David Michel-Tello, Renato Augusto Morales-Flores, Diana Flores-Estrada, Oscar Arrieta

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Polymorphonuclear-MDSC (PMN-MDSC) have emerged as an independent prognostic factor for survival in NSCLC. Similarly, cytokine profiles have been used to identify subgroups of NSCLC patients with different clinical outcomes. This prospective study investigated whether the percentage of circulating PMN-MDSC, in conjunction with the levels of plasma cytokines, was more informative of disease progression than the analysis of either factor alone. We analyzed the phenotypic and functional profile of peripheral blood T-cell subsets (CD3⁺, CD3⁺CD4⁺ and CD3⁺CD8⁺), neutrophils (CD66b⁺) and polymorphonuclear-MDSC (PMN-MDSC; CD66b⁺CD11b⁺CD15⁺CD14-) as well as the concentration of 14 plasma cytokines (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12 p70, IL-17A, IL-27, IL-29, IL-31, and IL-33, TNF-α, IFN-γ) in 90 treatment-naïve NSCLC patients and 25 healthy donors (HD). In contrast to HD, NSCLC patients had a higher percentage of PMN-MDSC and neutrophils (P < 0.0001) but a lower percentage of CD3⁺, CD3⁺CD4⁺ and CD3⁺CD8⁺ cells. PMN-MDSC% negatively correlated with the levels of IL1-β, IL-2, IL-27 and IL-29. Two groups of patients were identified according to the percentage of circulating PMN-MDSC. Patients with low PMN-MDSC (≤ 8%) had a better OS (22.1 months [95% CI 4.3–739.7]) than patients with high PMN-MDSC (9.3 months [95% CI 0–18.8]). OS was significantly different among groups of patients stratified by both PMN-MDSC% and cytokine levels. In sum, our findings provide evidence suggesting that PMN-MDSC% in conjunction with the levels IL-1β, IL-27, and IL-29 could be a useful strategy to identify groups of patients with potentially unfavorable prognoses.

Nur mit Berechtigung zugänglich

Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29. https://doi.org/10.3322/caac.21208 CrossRefPubMed

Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359:1367–1380. https://doi.org/10.1056/NEJMra0802714 CrossRefPubMed

Bremnes RM, Busund LT, Kilvaer TL et al (2016) The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer. J Thorac Oncol 11:789–800. https://doi.org/10.1016/j.jtho.2016.01.015 CrossRefPubMed

Mittal D, Gubin MM, Schreiber RD, Smyth MJ (2014) New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape. Curr Opin Immunol 27:16–25. https://doi.org/10.1016/j.coi.2014.01.004 CrossRefPubMedPubMedCentral

Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12:298–306. https://doi.org/10.1038/nrc3245 CrossRefPubMed

Yan X, Jiao SC (2015) Roles of tumor-infiltrating lymphocytes in non-small cell lung cancer recurrence and metastasis: a meta analysis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 37:406–414. https://doi.org/10.3881/j.issn.1000-503X.2015.04.007 PubMedCrossRef

Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, Herbst RS, Rimm DL (2015) Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst. https://doi.org/10.1093/jnci/dju435 CrossRefPubMedPubMedCentral

Kitamura T, Qian BZ, Pollard JW (2015) Immune cell promotion of metastasis. Nat Rev Immunol 15:73–86. https://doi.org/10.1038/nri3789 CrossRefPubMedPubMedCentral

Adah D, Hussain M, Qin L, Qin L, Zhang J, Chen X (2016) Implications of MDSCs-targeting in lung cancer chemo-immunotherapeutics. Pharmacol Res 110:25–34. https://doi.org/10.1016/j.phrs.2016.05.007 CrossRefPubMed

10.

Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, Gabrilovich D (2003) All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 63:4441–4449PubMed

11.

Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, Lush RM, Antonia S, Gabrilovich DI (2006) All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 66:9299–9307. https://doi.org/10.1158/0008-5472.CAN-06-1690 CrossRefPubMedPubMedCentral

12.

Talmadge JE, Gabrilovich DI (2013) History of myeloid-derived suppressor cells. Nat Rev Cancer 13:739–752. https://doi.org/10.1038/nrc3581 CrossRefPubMedPubMedCentral

13.

Serafini P, Borrello I, Bronte V (2006) Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16:53–65. https://doi.org/10.1016/j.semcancer.2005.07.005 CrossRefPubMed

14.

Swann JB, Smyth MJ (2007) Immune surveillance of tumors. J Clin Invest 117:1137–1146. https://doi.org/10.1172/JCI31405 CrossRefPubMedPubMedCentral

15.

Bronte V, Brandau S, Chen SH et al (2016) Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 7:12150. https://doi.org/10.1038/ncomms12150 CrossRefPubMedPubMedCentral

16.

Kolahian S, Oz HH, Zhou B, Griessinger CM, Rieber N, Hartl D (2016) The emerging role of myeloid-derived suppressor cells in lung diseases. Eur Respir J 47:967–977. https://doi.org/10.1183/13993003.01572-2015 CrossRefPubMed

17.

Huang A, Zhang B, Wang B, Zhang F, Fan KX, Guo YJ (2013) Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol Immunother 62:1439–1451. https://doi.org/10.1007/s00262-013-1450-6 CrossRefPubMed

18.

Srivastava MK, Bosch JJ, Thompson JA, Ksander BR, Edelman MJ, Ostrand-Rosenberg S (2008) Lung cancer patients’ CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother 57:1493–1504. https://doi.org/10.1007/s00262-008-0490-9 CrossRefPubMedPubMedCentral

19.

Haverkamp JM, Smith AM, Weinlich R et al (2014) Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity 41:947–959. https://doi.org/10.1016/j.immuni.2014.10.020 CrossRefPubMedPubMedCentral

20.

Liu CY, Wang YM, Wang CL et al (2010) Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14(−)/CD15+/CD33+ myeloid-derived suppressor cells and CD8+T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 136:35–45. https://doi.org/10.1007/s00432-009-0634-0 CrossRefPubMed

21.

Srivastava MK, Andersson A, Zhu L, Harris-White M, Lee JM, Dubinett S, Sharma S (2012) Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy 4:291–304. https://doi.org/10.2217/imt.11.178 CrossRefPubMedPubMedCentral

22.

Vetsika EK, Koinis F, Gioulbasani M, Aggouraki D, Koutoulaki A, Skalidaki E, Mavroudis D, Georgoulias V, Kotsakis A (2014) A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. J Immunol Res. https://doi.org/10.1155/2014/659294 PubMedPubMedCentralCrossRef

23.

Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166:678–689CrossRefPubMed

24.

Marvel D, Gabrilovich DI (2015) Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest 125:3356–3364. https://doi.org/10.1172/JCI80005 CrossRefPubMedPubMedCentral

25.

Zhang G, Huang H, Zhu Y, Yu G, Gao X, Xu Y, Liu C, Hou J, Zhang X (2015) A novel subset of B7-H3 + CD14 + HLA-DR-/low myeloid-derived suppressor cells are associated with progression of human NSCLC. Oncoimmunology 4:e977164. https://doi.org/10.4161/2162402X.2014.977164 CrossRefPubMedPubMedCentral

26.

Feng PH, Lee KY, Chang YL et al (2012) CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. Am J Respir Crit Care Med 186:1025–1036. https://doi.org/10.1164/rccm.201204-0636OC CrossRefPubMedPubMedCentral

27.

Ugel S, De Sanctis F, Mandruzzato S, Bronte V (2015) Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest 125:3365–3376. https://doi.org/10.1172/JCI80006 CrossRefPubMedPubMedCentral

28.

Condamine T, Ramachandran I, Youn JI, Gabrilovich DI (2015) Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med 66:97–110. https://doi.org/10.1146/annurev-med-051013-052304 CrossRefPubMed

29.

Barrera L, Montes-Servin E, Barrera A, Ramirez-Tirado LA, Salinas-Parra F, Banales-Mendez JL, Sandoval-Rios M, Arrieta O (2015) Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis. Ann Oncol 26:428–435. https://doi.org/10.1093/annonc/mdu549 CrossRefPubMed

30.

Barrera L, Montes-Servin E, Hernandez-Martinez JM, Garcia-Vicente MLA, Montes-Servin E, Herrera-Martinez M, Crispin JC, Borbolla-Escoboza JR, Arrieta O (2017) CD47 overexpression is associated with decreased neutrophil apoptosis/phagocytosis and poor prognosis in non-small-cell lung cancer patients. Br J Cancer 117:385–397. https://doi.org/10.1038/bjc.2017.173 CrossRefPubMedPubMedCentral

31.

Rodriguez PC, Quiceno DG, Zabaleta J et al (2004) Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 64:5839–5849. https://doi.org/10.1158/0008-5472.CAN-04-0465 CrossRefPubMed

32.

Zea AH, Rodriguez PC, Atkins MB et al (2005) Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65:3044–3048. https://doi.org/10.1158/0008-5472.CAN-04-4505 CrossRefPubMed

33.

Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T (2011) Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer. Anticancer Res 31:2995–2998PubMed

34.

Parker KH, Beury DW, Ostrand-Rosenberg S (2015) Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. Adv Cancer Res 128:95–139. https://doi.org/10.1016/bs.acr.2015.04.002 CrossRefPubMedPubMedCentral

35.

Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V (2014) Myeloid-derived suppressor cell heterogeneity in human cancers. Ann NY Acad Sci 1319:47–65. https://doi.org/10.1111/nyas.12469 CrossRefPubMed

36.

Coffelt SB, Wellenstein MD, de Visser KE (2016) Neutrophils in cancer: neutral no more. Nat Rev Cancer 16:431–446. https://doi.org/10.1038/nrc.2016.52 CrossRefPubMed

37.

Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12:253–268. https://doi.org/10.1038/nri3175 CrossRefPubMedPubMedCentral

38.

Reppert S, Koch S, Finotto S (2012) IL-17A is a central regulator of lung tumor growth. Oncoimmunology 1:783–785. https://doi.org/10.4161/onci.19735 CrossRefPubMedPubMedCentral

39.

Yang B, Kang H, Fung A, Zhao H, Wang T, Ma D (2014) The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis. Mediators Inflamm. https://doi.org/10.1155/2014/623759 CrossRefPubMedPubMedCentral

40.

Chen X, Wan J, Liu J, Xie W, Diao X, Xu J, Zhu B, Chen Z (2010) Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 69:348–354. https://doi.org/10.1016/j.lungcan.2009.11.013 CrossRefPubMed

41.

Chen X, Xie Q, Cheng X, Diao X, Cheng Y, Liu J, Xie W, Chen Z, Zhu B (2010) Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells. Cancer Sci 101:2384–2390. https://doi.org/10.1111/j.1349-7006.2010.01684.x CrossRefPubMed

42.

Campian JL, Ye X, Brock M, Grossman SA (2013) Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer Invest 31:183–188. https://doi.org/10.3109/07357907.2013.767342 CrossRefPubMedPubMedCentral

43.

Grossman SA, Ellsworth S, Campian J, Wild AT, Herman JM, Laheru D, Brock M, Balmanoukian A, Ye X (2015) Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors. J Natl Compr Cancer Netw JNCCN 13:1225–1231CrossRef

44.

Arrieta O, Michel Ortega RM, Villanueva-Rodriguez G, Serna-Thome MG, Flores-Estrada D, Diaz-Romero C, Rodriguez CM, Martinez L, Sanchez-Lara K (2010) Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer 10:50. https://doi.org/10.1186/1471-2407-10-50 CrossRefPubMedPubMedCentral

45.

Lee PP, Yee C, Savage PA et al (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5:677–685. https://doi.org/10.1038/9525 CrossRefPubMed

46.

Rodriguez PC, Ochoa AC (2008) Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 222:180–191. https://doi.org/10.1111/j.1600-065X.2008.00608.x CrossRefPubMedPubMedCentral

47.

Apte RN, Krelin Y, Song X et al (2006) Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur J Cancer 42:751–759. https://doi.org/10.1016/j.ejca.2006.01.010 CrossRefPubMed

48.

Carmi Y, Rinott G, Dotan S, Elkabets M, Rider P, Voronov E, Apte RN (2011) Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. J Immunol 186:3462–3471. https://doi.org/10.4049/jimmunol.1002901 CrossRefPubMed

49.

Song X, Krelin Y, Dvorkin T, Bjorkdahl O, Segal S, Dinarello CA, Voronov E, Apte RN (2005) CD11b+/Gr-1 + immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J Immunol 175:8200–8208CrossRefPubMed

50.

Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S (2007) Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 67:10019–10026. https://doi.org/10.1158/0008-5472.CAN-07-2354 CrossRefPubMedPubMedCentral

51.

Kiyohara C, Horiuchi T, Takayama K, Nakanishi Y (2010) IL1B rs1143634 polymorphism, cigarette smoking, alcohol use, and lung cancer risk in a Japanese population. J Thorac Oncol 5:299–304. https://doi.org/10.1097/JTO.0b013e3181c8cae3 CrossRefPubMed

52.

Li Y, Zhao W, Zhao Z et al (2015) IL1B gene polymorphisms, age and the risk of non-small cell lung cancer in a Chinese population. Lung Cancer 89:232–237. https://doi.org/10.1016/j.lungcan.2015.06.009 CrossRefPubMed

53.

Zienolddiny S, Ryberg D, Maggini V, Skaug V, Canzian F, Haugen A (2004) Polymorphisms of the interleukin-1 beta gene are associated with increased risk of non-small cell lung cancer. Int J Cancer J Int Cancer 109:353–356. https://doi.org/10.1002/ijc.11695 CrossRef

54.

Landvik NE, Hart K, Skaug V, Stangeland LB, Haugen A, Zienolddiny S (2009) A specific interleukin-1B haplotype correlates with high levels of IL1B mRNA in the lung and increased risk of non-small cell lung cancer. Carcinogenesis 30:1186–1192. https://doi.org/10.1093/carcin/bgp122 CrossRefPubMed

55.

Guma M, Ronacher L, Liu-Bryan R, Takai S, Karin M, Corr M (2009) Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. Arthritis Rheum 60:3642–3650. https://doi.org/10.1002/art.24959 CrossRefPubMedPubMedCentral

56.

Joosten LA, Netea MG, Fantuzzi G et al (2009) Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum 60:3651–3662. https://doi.org/10.1002/art.25006 CrossRefPubMedPubMedCentral

57.

Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, Group CT (2017) Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390:1833–1842. https://doi.org/10.1016/S0140-6736(17)32247-X CrossRefPubMed

58.

Mauti LA, Le Bitoux MA, Baumer K, Stehle JC, Golshayan D, Provero P, Stamenkovic I (2011) Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation. J Clin Invest 121:2794–2807. https://doi.org/10.1172/JCI41936 CrossRefPubMedPubMedCentral

59.

Correale P, Tindara Miano S, Remondo C et al (2009) Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine. Cancer Biol Therapy 8:497–502. https://doi.org/10.4161/cbt.8.6.7593 CrossRef

60.

Ridolfi L, Bertetto O, Santo A et al (2011) Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial. Int J Oncol 39:1011–1017. https://doi.org/10.3892/ijo.2011.1099 PubMedCrossRef

61.

Kachroo P, Lee MH, Zhang L et al (2013) IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. J Exp Clin Cancer Res CR 32:97. https://doi.org/10.1186/1756-9966-32-97 CrossRefPubMed

62.

Lee MH, Kachroo P, Pagano PC et al (2014) Combination treatment with apricoxib and IL-27 enhances inhibition of epithelial-mesenchymal transition in human lung cancer cells through a STAT1 dominant pathway. J Cancer Sci Ther 6:468–477. https://doi.org/10.4172/1948-5956.1000310 CrossRefPubMedPubMedCentral

63.

Mattei F, Schiavoni G, Sestili P et al (2012) IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment. Neoplasia 14:1223–1235CrossRefPubMedPubMedCentral

64.

Diakowska D, Lewandowski A, Markocka-Maczka K, Grabowski K (2013) Concentration of serum interleukin-27 increase in patients with lymph node metastatic gastroesophageal cancer. Adv Clin Exp Med 22:683–691PubMed

65.

Lu D, Zhou X, Yao L, Liu C, Jin F, Wu Y (2014) Clinical implications of the interleukin 27 serum level in breast cancer. J Investig Med 62:627–631. https://doi.org/10.2310/JIM.0000000000000046 CrossRefPubMed

66.

Gonin J, Carlotti A, Dietrich C et al (2013) Expression of IL-27 by tumor cells in invasive cutaneous and metastatic melanomas [corrected]. PloS One 8:e75694. https://doi.org/10.1371/journal.pone.0075694 CrossRefPubMedPubMedCentral

67.

Nishino R, Takano A, Oshita H et al (2011) Identification of Epstein–Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res 17:6272–6286. https://doi.org/10.1158/1078-0432.CCR-11-0060 CrossRefPubMed

68.

Fujie H, Tanaka T, Tagawa M, Kaijun N, Watanabe M, Suzuki T, Nakayama K, Numasaki M (2011) Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer. Cancer Sci 102:1977–1990. https://doi.org/10.1111/j.1349-7006.2011.02079.x CrossRefPubMed

69.

Barrera L, Montes-Servin E, Hernandez-Martinez JM, Orozco-Morales M, Montes-Servin E, Arrieta O (2017) P1.07-040 prognosis-relevant subgroups in NSCLC according to granulocytic myeloid-derived suppressor cell frequency and cytokine levels. J Thorac Oncol 12:S2011–S2. https://doi.org/10.1016/j.jtho.2017.09.959.POSTER CrossRef

70.

Arrieta O, Morales-Flores R, Garcia-Vicente A, Montes-Servin E, Salinas-Parra F, Barrera L (2015) ORAL41.03 myeloid derived suppressor cells and their clinical relevance in non-small cell lung cancer. J Thorac Oncol 10(9):S255

Titel: Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancer
verfasst von: Lourdes Barrera
Edgar Montes-Servín
Juan-Manuel Hernandez-Martinez
Mario Orozco-Morales
Elizabeth Montes-Servín
David Michel-Tello
Renato Augusto Morales-Flores
Diana Flores-Estrada
Oscar Arrieta
Publikationsdatum: 04.07.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 9/2018
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-018-2196-y

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancer

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2018

Reply to “Pseudoprogression”: more than semantics

Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab

Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette–Guerin for patients with non-muscle invasive bladder cancer

Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer

Correction to: High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer

Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie